Cen Biotech Stock Performance
| CENBF Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and CEN Biotech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CEN Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, CEN Biotech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 1908.00 | |
| Total Cashflows From Investing Activities | 9937.00 |
CEN |
CEN Biotech Relative Risk vs. Return Landscape
If you would invest 0.01 in CEN Biotech on November 8, 2025 and sell it today you would earn a total of 0.00 from holding CEN Biotech or generate 0.0% return on investment over 90 days. CEN Biotech is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than CEN, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CEN Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CEN Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CEN Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CEN Biotech generated a negative expected return over the last 90 days | |
| CEN Biotech has some characteristics of a very speculative penny stock | |
| CEN Biotech has accumulated 31.55 K in total debt. CEN Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist CEN Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, CEN Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CEN Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CEN to invest in growth at high rates of return. When we think about CEN Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 626.87 K. Net Loss for the year was (18.9 M) with profit before overhead, payroll, taxes, and interest of 626.87 K. | |
| CEN Biotech has accumulated about 66.05 K in cash with (335.5 K) of positive cash flow from operations. | |
| Roughly 54.0% of the company shares are held by company insiders |
CEN Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CEN Pink Sheet often depends not only on the future outlook of the current and potential CEN Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CEN Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 32.7 M | |
| Cash And Short Term Investments | 193.2 K |
CEN Biotech Fundamentals Growth
CEN Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CEN Biotech, and CEN Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CEN Pink Sheet performance.
| Return On Asset | -0.1 | |||
| Profit Margin | (3.00) % | |||
| Operating Margin | (1.28) % | |||
| Current Valuation | 8.36 M | |||
| Shares Outstanding | 64.13 M | |||
| Price To Earning | 0.64 X | |||
| Price To Sales | 3.44 X | |||
| Revenue | 626.87 K | |||
| EBITDA | (18.42 M) | |||
| Cash And Equivalents | 66.05 K | |||
| Total Debt | 31.55 K | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (335.5 K) | |||
| Earnings Per Share | (0.41) X | |||
| Total Asset | 8.44 M | |||
About CEN Biotech Performance
By analyzing CEN Biotech's fundamental ratios, stakeholders can gain valuable insights into CEN Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CEN Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CEN Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. The company was incorporated in 2013 and is based in Windsor, Canada. Cen Biotech operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about CEN Biotech performance evaluation
Checking the ongoing alerts about CEN Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CEN Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CEN Biotech generated a negative expected return over the last 90 days | |
| CEN Biotech has some characteristics of a very speculative penny stock | |
| CEN Biotech has accumulated 31.55 K in total debt. CEN Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist CEN Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, CEN Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CEN Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CEN to invest in growth at high rates of return. When we think about CEN Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 626.87 K. Net Loss for the year was (18.9 M) with profit before overhead, payroll, taxes, and interest of 626.87 K. | |
| CEN Biotech has accumulated about 66.05 K in cash with (335.5 K) of positive cash flow from operations. | |
| Roughly 54.0% of the company shares are held by company insiders |
- Analyzing CEN Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CEN Biotech's stock is overvalued or undervalued compared to its peers.
- Examining CEN Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CEN Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CEN Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CEN Biotech's pink sheet. These opinions can provide insight into CEN Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CEN Pink Sheet analysis
When running CEN Biotech's price analysis, check to measure CEN Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CEN Biotech is operating at the current time. Most of CEN Biotech's value examination focuses on studying past and present price action to predict the probability of CEN Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CEN Biotech's price. Additionally, you may evaluate how the addition of CEN Biotech to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |